Quick Answer
Benitec Biopharma Inc. reported Research And Development Expense of $18.33 million for the year ending 2025.
- Benitec Biopharma Inc. showed an increase of +17.4% in Research And Development Expense from 2024 to 2025.
- This data is from Benitec Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on September 22, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $423.0 thousand | Q4 2019: $599.0 thousand | Q1 2020: $805.0 thousand | Q3 2020: $774.0 thousand | Q4 2020: $1.17 million | Q1 2021: $2.76 million | Q3 2021: $2.78 million | Q4 2021: $3.15 million | Q1 2022: $2.17 million | Q3 2022: $2.66 million | Q4 2022: $3.76 million | Q1 2023: $3.17 million | Q3 2023: $4.43 million | Q4 2023: $5.10 million | Q1 2024: $2.57 million | Q3 2024: $3.59 million | Q4 2024: $5.39 million | Q1 2025: $5.98 million | Q2 2025: $2.87 million | Q3 2025: $3.37 million | Q4 2025: $5.83 million.
- Over the full 7 years of available data (2019 to 2025), Benitec Biopharma Inc.'s Research And Development Expense has grown by 301.4%.
- Historical annual values: Fiscal year 2025: $18.33 million | Fiscal year 2024: $15.61 million | Fiscal year 2023: $12.77 million | Fiscal year 2022: $11.27 million | Fiscal year 2021: $7.02 million | Fiscal year 2020: $3.00 million | Fiscal year 2019: $4.57 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: